Agendia’s MammaPrint and BluePrint Breast Cancer Tests to Be Highlighted at San Antonio Symposium

Guía de Regalos

Satellite Symposium and Dinner Presentation Will Offer Latest
Insights on Genomic Testing and Molecular Subtyping

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–New breast cancer research highlighting the value of Agendia’s
MammaPrint® and BluePrint® genomic tests will be presented in 10
scientific posters at the upcoming 2015 San Antonio Breast Cancer
Symposium (SABCS).

Four of the posters will provide new findings from the NBRST trial,
which encompasses results from more than 1,000 patients. The trial has
produced results that consistently underscore the unique ability of
functional molecular subtyping, compared to standard clinicopathologic
classification alone, to better predict those patients who will respond
to chemotherapy and/or targeted therapy.

Agendia will also offer a satellite symposium on “The Significance of
Prospective Randomized Trials in Genomic Testing Validation and the
Advancement of Precision Medicine,” featuring two of the world’s leading
scientists in genomic medicine. The symposium will be led by guest
speakers Emiel Rutgers, F.R.C.S., M.D., Ph.D., head of the Department of
Surgery at the Netherlands Cancer Institute, and Laura van ’t Veer,
Ph.D., Leader, Breast Oncology Program and Director, Applied Genomics at
University of California, San Francisco. They will discuss the MINDACT
trial design and the significance of prospective randomized trials in
genomic testing validation. The symposium will be held Wednesday, Dec. 9
at 2 p.m. in the Exhibit Hall’s Product Theater.

On Thursday, Dec.10, Agendia will host a dinner presentation on
Molecular Subtypes. Peter Beitsch, M.D. and Pat Whitworth, M.D. of
Targeted Medical Education will discuss functional molecular subtypes
and emerging research in the management of early stage breast cancer.
The dinner will take place at Bohanans Prime Steaks and Seafood at 219
East Houston Street, 2nd Floor, in San Antonio. A welcome reception
starts at 6:30 P.M. with the presentation beginning at 7:00 p.m.

For more information about both of these events, please inquire at the
Agendia conference Booth #518.

The Agendia-related poster presentations at SABCS and their authors are:

Wednesday, December 9

Poster P1-14-05: Three distinct HER2 subtypes identified by
BluePrint 80-gene functional subtyping predict treatment-specific
response in the prospective neo-adjuvant NBRST registry (NBRST)

Authors: Pat Whitworth, Peter Beitsch, Paul Baron, Jennifer
Beatty, James V Pellicane, Mary K. Murray, Carrie L Dul, Angela M
Mislowsky, Charles H Nash, Paul D Richards, Laura A Lee, Lisette
Stork-Sloots, Femke de Snoo, Sarah Untch, Mark Gittleman, Stephanie
Akbari, Michael C Rotkis

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

P1-14-10: Phase II trial of neoadjuvant chemotherapy (NCT) with
carboplatin and nab-paclitaxel in patients with triple negative locally
advanced and inflammatory breast cancer (TNBC) (Somlo)

Authors: Somlo G, Chung S, Frankel P, Hurria A, Koehler S, Kruper L,
Mortimer JE, Paz B, Robinson K, Taylor L, Vito C, Waisman J, Yeon C, Yim
J, Yuan Y, Tong T

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

Thursday, December 10

Poster P3-07-67: Chemosensitivity and endocrine sensitivity
predicted by MammaPrint and BluePrint in clinical Luminal patients in
the prospective NBRST study (NBRST)

Authors: James V Pellicane, Pat Whitworth, Peter Beitsch, Paul Baron,
Jennifer Beatty, Mary Murray, Carrie L Dul, Angela M Mislowsky, Charles
H Nash, Paul D Richards, Laura A Lee, Lisette Stork-Sloots, Femke de
Snoo, Sarah Untch, Mark Gittleman, Stephanie Akbari, Michael C Rotkis

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

Poster OT2-03-01: Measuring the Impact of MammaPrint on treatment
in Breast Cancer Patients: A Prospective Registry (IMPaCt)

Authors: Lowell L. Hart, Sarah Untch, Lisette Stork-Sloots

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

Friday, December 11

Poster P4-14-10: Pertuzumab overcomes chemotherapy/trastuzumab
resistance in ER+/Her2+ tumors classified as Luminal functional subtype
by the 80-gene BluePrint assay in the prospective Neo-adjuvant Breast
Registry Symphony Trial (NBRST)

Authors: Peter Beitsch, Pat Whitworth, Paul Baron, Jennifer Beatty,
James V Pellicane, Mary K. Murray, Carrie L Dul, Angela M Mislowsky,
Charles H Nash, Paul D Richards, Laura A Lee, Lisette Stork-Sloots,
Femke de Snoo, Sarah Untch, Mark Gittleman, Stephanie Akbari, Michael C
Rotkis

Exhibit Halls A-B, Time: 7:30 a.m. – 9:00 a.m.

Poster P4-14-29: One-third of HER2 positive patients have 80-gene
Luminal subtype that is resistant to Chemo-trastuzumab but sensitive to
Chemo-trastuzumab-pertuzumab: critical implications for the adjuvant
setting from the NBRST neoadjuvant registry (NBRST)

Authors: Peter Beitsch, Pat Whitworth, Paul Baron, Jennifer Beatty,
James V Pellicane, Mary K. Murray, Carrie L Dul, Angela M Mislowsky,
Charles H Nash, Paul D Richards, Laura A Lee, Lisette Stork-Sloots,
Femke de Snoo, Sarah Untch, Mark Gittleman, Stephanie Akbari, Michael C
Rotkis

Exhibit Halls A-B, Time: 7:30 a.m. – 9:00 a.m.

Poster P5-13-07: An Investigator-Initiated Registry Trial of
Simple Oral Therapy for Low Risk Breast Cancer (FHCRC)

Authors: VK Gadi, Courtney Preusse, Kristine Calhoun, Janice Kim, Hannah
Linden, Mara Rendi, Ruth Etzioni, Ted Gooley, Gary Lyman, Lisette Stork,
Vastiaan van der Baan, Neil Barth, Habib Rahbar

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

Saturday, December 12

Poster P6-05-07: Improving personalized management of primary
breast cancer: Mammaprint® Risk stratification and Blueprint® molecular
subtyping

Authors: Lekha Mikkilineni, Laura K. Austin, Kimberly Limentani, Rebecca
J. Jaslow, Tiffany P. Avery, Juan Palazzo, and Massimo Cristofanilli

Exhibit Halls A-B, Time: 7:30 a.m. – 9:00 a.m.

Poster P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα
binding and gene expression profiles (AFTER)

Authors: Sabine C. Linn, Tesa M. Severson, Ekaterina Nevedomskaya,
Justine Peeters, Annelot van Rossum, Thomas Kuilman, Oscar Krijgsman,
Ines Goossens, Annuska Glas, Rutger Koornstra, Daniel Peeper, Jelle
Wesseling, Iris M. Simon, Lodewyk Wessels, Wilbert Zwart

Exhibit Halls A-B, Time: 7:30 a.m. – 9:00 a.m.

Poster P6-09-01: Identification of tumors with an indolent
disease course: MammaPrint Ultralow signature validation in a
retrospective analysis of a Swedish randomized tamoxifen trial (STO)

Authors: Laura J Esserman, Carlie K Thompson, Christina Yau, Laura J van
‘t Veer, Alexander D Borowsky, Nicholas P Tobin, Bo Nordenskjöld, Tommy
Fornander, Olle Stål, Christopher C Benz, Linda S Lindström

Exhibit Halls A-B, Time 7:30 a.m. – 9:00 a.m.

The 70-gene MammaPrint test, an FDA-cleared FFPE, second-generation
breast cancer recurrence assay, provides definitive High Risk or Low
Risk information about breast cancer recurrence, with no “intermediate”
results. Agendia’s companion BluePrint test is the only widely available
assay that provides functional molecular subtypes. It delivers enhanced
information about which patients may or may not respond to neoadjuvant
(preoperative) therapy and also assists physicians and their patients in
determining the best course for therapy. The Agendia tests have
substantial insurance coverage encompassing an estimated 200 million
lives, including coverage by Medicare and regional and national
insurers. To learn more about the tests, SABCS attendees can visit Booth
#518.

SABCS 2015 will be held at the Henry Gonzales Conference Center in San
Antonio, Texas, USA, Dec. 8-12, 2015.

Resources for further reference

* MammaPrint/Blueprint Predict Response to Targeted Treatment Regimens press
release

* NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to
Predict Prognosis press
release

* Independent comparison validates molecular
subtyping
(includes video)

* RASTER prospective study concludes some can safely forego chemotherapy press
release

About Agendia

Agendia is a privately owned, leading molecular diagnostic company that
develops and markets FFPE-based genomic diagnostic products, which help
support physicians with their complex treatment decisions. Agendia’s
breast cancer suite was developed using an unbiased gene selection by
analyzing the complete human genome.

This includes the MammaPrint test, which is the only FDA-cleared test
for women of all ages and which is not limited by estrogen receptor
status. Agendia’s suite of tests includes BluePrint, which in
combination with MammaPrint provides the only commercially available way
to predict response to current breast cancer chemotherapy and targeted
therapy regimens. In addition to MammaPrint and BluePrint, which is a
molecular subtyping assay that provides deeper insight leading to more
clinically actionable biology, Agendia also offers TargetPrint®, an
ER/PR/HER2 expression assay.

Agendia’s tests help physicians assess a breast cancer patient’s
individual risk for metastasis, which patients may benefit from chemo,
hormonal, or combination therapy, and which patients may not require
these treatments and can instead be treated with other, less arduous and
less costly methods.

In addition, Agendia has a pipeline of other genomic products in
development. The company collaborates with pharmaceutical companies,
leading cancer centers and academic groups to develop companion
diagnostic tests in the area of oncology and is a critical partner in
the I-SPY 2 and the MINDACT trials. For more information, visit www.agendia.com.

Contacts

Dowling & Dennis Public Relations
Liz Dowling, 415-388-2794
(Medical & Consumer Media)
Liz@DowlingDennis.net
or
SPJ
Financiële & Corporate Communicatie
Amsterdam, The Netherlands
Léon
Melens, +31 20 647 81 81
lmelens@spj.nl